2022 Department of Medicine Grand Rounds | New Frontiers in Hereditary Gastrointestinal Cancer Syndrome Care
Lynch Syndrome (LS) affects 1:250 individuals or about 1.2 million people in the United States (US), a number similar to the HIV infected population. People who have LS have a significantly increased risk of developing colorectal cancer. There is also an increased risk of developing other types of cancers, such as endometrial (uterine), stomach, ovarian, small bowel (intestinal), pancreatic, prostate, urinary tract, liver, kidney, and bile duct cancers. LS is caused by a mutation in one of five mismatch repair genes, MLH1, MSH2/EPCAM, MSH6, or PMS2. Family members of mutation carriers have up to a 50% chance of having LS themselves. Lifetime risk of different cancers in LS ranges between 10-80% depending on the gene impacted (high risk (MLH1 or MSH2/EPCAM) or low risk (MSH6, PMS2)) and age (</≥50 years). There are evidence-based guidelines that can decrease cancer incidence and mortality associated with LS, but are rarely practiced due to a lack of identification of LS patients or a lack of understanding of current guidelines.
This activity is necessary as there are evidence-based guidelines and new chemoprevention strategies that can decrease cancer incidence and mortality associated with LS, but are rarely practiced due to a lack of identification of LS patients or a lack of understanding of current guidelines. There is a gap in identifying LS patients prior to the development of cancer which would be due to a number of factors: 1) Lack of awareness of LS and its clinical relevance and management 2) Lack of understanding the family history of cancer 3) Lack of clinical tools or resources (genetic counseling testing) to help with the identification of LS patients.
Physicians and advanced practice providers.
- Identify patients with a possible inherited risk of cancer.
- Assess whether a patient should undergo genetic testing.
- Discuss new prevention measures for patients with an underlying hereditary syndrome.
- Discuss possible barriers and biases which may impact patient care (i.e., race, ethnicity, language, gender identity/orientation, age, socioeconomic status, attitudes, feelings, or other characteristics).
Virtual Meeting- Zoom
Gregory Idos, MD, MS Associate Professor of Clinical Medicine, Divisions of Gastroenterology & Clinical Cancer Genomics, Center for Precision Medicine; City of Hope
Dr. Idos has indicated that he does not have anything to disclose.
Dr. Idos will be discussing the off-label or investigational use of Guselkumab and Nous-209.
ACCREDITATION STATEMENT: City of Hope is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CREDIT DESIGNATION: City of Hope designates this live webinar for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The following credit type(s) are being offered for this course:
• AMA PRA Category 1 Credit™ 1.0
The following may apply AMA PRA Category 1 Credit™ for license renewal:
Registered Nurses: Nurses may report up to 1.0 credit hours toward the continuing education requirements for license renewal by their state Board of Registered Nurses (BRN). AMA PRA Category 1 Credit™ may be noted on the license renewal application in lieu of a BRN provider number.
Physician Assistants: The National Commission on Certification of Physicians Assistants states that AMA PRA Category 1 Credit™ accredited courses are acceptable for CME requirements for recertification.
- 1.00 AMA PRA Category 1 Credit™City of Hope is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
City of Hope designates this 2022 Department of Medicine Grand Rounds | New Frontiers in Hereditary Gastrointestinal Cancer Syndrome Care for a maximum of 1.00 AMA PRA Category 1 Credit™ requirements. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 1.00 Attendance